Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen

CARLSBAD, Calif. , Aug. 30, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $40 million milestone payment from Biogen associated with the pricing approval of SPINRAZA ® (nusinersen) in Japan . SPINRAZA was approved for individuals with